April 26, 2019 Healthcare, Top Market News 0 Comments Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS) By Carrie Williams
[Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS)] In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Aclaris Therapeutics Inc (ACRS ? Research Report), with a price target of $50. The company?s shares closed yesterday at $6.83, close to its 52-week low of $5.04.
?We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of 50 USD.
"Aclaris anticipates that its cash, cash equivalents and marketable securities as of December 31, 2019, will be sufficient to fund its operations into the third quarter of 2021, without giving effect to any potential business development transactions or financing activities."
Aclaris Says FDA Clears IND To Evaluate ATI-450 MK2 Inhibitor - Quick Facts
Jun. 17, 2020, 01:35 PM
(RTTNews) - Clinical-stage biopharmaceutical company Aclaris Therapeutics, Inc. (ACRS) announced Wednesday that the U.S. Food and Drug Administration (FDA) has allowed an investigational new drug (IND) application to evaluate ATI-450, its oral investigational MK2 inhibitor compound, in hospitalized patients with COVID-19.
Aclaris is supporting an investigator-initiated trial of ATI-450 for cytokine release syndrome (CRS) in 36 hospitalized patients with COVID-19, and will provide funding and clinical drug supply to the University of Kansas Medical Center (KUMC), the sponsor of the trial.
vielleicht sollte ich mal ne Verkaufsorder mit 4 Euro einstellen, dann kann mir das mit permarket Explosion bei den Amis nicht mehr passieren. Ansonsten kannst hier keine Gewinne realisieren, wenn man nicht den ganzen Tag am Computer ist...
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
WAYNE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, for the treatment of moderate to severe atopic dermatitis (AD). ATI-1777 is another compound generated from the Aclaris KINect™ drug discovery platform, and was specifically developed as a topical “soft” drug.